113 related articles for article (PubMed ID: 33722157)
1. Immuno-toxicological evaluation of her1 cancer vaccine in non-human primates: a 6-month subcutaneous study.
Mancebo Rodríguez A; Bergado Báez G; Acosta Lago E; León Goñi A; Blanco Gámez D; Fuentes Morales D; Hernández Fernández DR; Sánchez Ramírez B; Pérez Barreda A; Casacó Parada Á
Immunopharmacol Immunotoxicol; 2021 Jun; 43(3):283-290. PubMed ID: 33722157
[No Abstract] [Full Text] [Related]
2. Non-clinical immuno-toxicological evaluation of HER1 cancer vaccine in non-human primates: a 12-month study.
Barro AM; Rivero AI; Goñi AL; Navarro BO; Angarica MM; Ramírez BS; Bedoya DM; Triana CG; Rodríguez AM; Parada ÁC
Vaccine; 2012 Dec; 31(1):89-95. PubMed ID: 23142132
[TBL] [Abstract][Full Text] [Related]
3. Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial.
Caballero I; Aira LE; Lavastida A; Popa X; Rivero J; González J; Mesa M; González N; Coba K; Lorenzo-Luaces P; Wilkinson B; Santiesteban Y; Santiesteban Y; Troche M; Suarez E; Crombet T; Sánchez B; Casacó A; Macías A; Mazorra Z
Front Pharmacol; 2017; 8():263. PubMed ID: 28539888
[TBL] [Abstract][Full Text] [Related]
4. HER1-ECD vaccination dispenses with emulsification to elicit HER1-specific anti-proliferative effects.
Alpízar YA; Ramírez BS; Fernández DR; Capote AR; Hidalgo GG; Rodríguez RP; Molina LE
Hum Vaccin; 2009 Mar; 5(3):158-65. PubMed ID: 19246985
[TBL] [Abstract][Full Text] [Related]
5. Very small size proteoliposomes (VSSP) and Montanide combination enhance the humoral immuno response in a GnRH based vaccine directed to prostate cancer.
Aguilar FF; Barranco JJ; Fuentes EB; Aguilera LC; Sáez YL; Santana MD; Vázquez EP; Baker RB; Acosta OR; Pérez HG; Nieto GG
Vaccine; 2012 Oct; 30(46):6595-9. PubMed ID: 22921738
[TBL] [Abstract][Full Text] [Related]
6. Complete antitumor protection by perioperative immunization with GM3/VSSP vaccine in a preclinical mouse melanoma model.
Gabri MR; Mazorra Z; Ripoll GV; Mesa C; Fernandez LE; Gomez DE; Alonso DF
Clin Cancer Res; 2006 Dec; 12(23):7092-8. PubMed ID: 17145833
[TBL] [Abstract][Full Text] [Related]
7. HER1-based vaccine: Simultaneous activation of humoral and cellular immune response.
Bergado Báez G; Hernández Fernández DR; Mazorra Herrera Z; Sánchez Ramírez B
Semin Oncol; 2018 Jan; 45(1-2):75-83. PubMed ID: 30318087
[TBL] [Abstract][Full Text] [Related]
8. Repeated dose intramuscular injection of the CIMAvax-EGF vaccine in Sprague Dawley rats induces local and systemic toxicity.
Mancebo A; Casacó A; González B; Ledón N; Sorlozabal J; León A; Gómez D; González Y; Bada AM; González C; Arteaga ME; Ramírez H; Fuentes D
Vaccine; 2012 May; 30(22):3329-38. PubMed ID: 22433960
[TBL] [Abstract][Full Text] [Related]
9. Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant.
Ramírez BS; Pestana ES; Hidalgo GG; García TH; Rodríguez RP; Ullrich A; Férnandez LE
Int J Cancer; 2006 Nov; 119(9):2190-9. PubMed ID: 16841332
[TBL] [Abstract][Full Text] [Related]
10. A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo.
Carr A; Mazorra Z; Alonso DF; Mesa C; Valiente O; Gomez DE; Perez R; Fernandez LE
Melanoma Res; 2001 Jun; 11(3):219-27. PubMed ID: 11468510
[TBL] [Abstract][Full Text] [Related]
11. Experimental studies of a vaccine formulation of recombinant human VEGF antigen with aluminum phosphate.
Pérez Sánchez L; Morera Díaz Y; Bequet-Romero M; Ramses Hernández G; Rodríguez Y; Castro Velazco J; Puente Pérez P; Ayala Avila M; Gavilondo JV
Hum Vaccin Immunother; 2015; 11(8):2030-7. PubMed ID: 25891359
[TBL] [Abstract][Full Text] [Related]
12. Montanide ISA™ 201 adjuvanted FMD vaccine induces improved immune responses and protection in cattle.
Dar P; Kalaivanan R; Sied N; Mamo B; Kishore S; Suryanarayana VV; Kondabattula G
Vaccine; 2013 Jul; 31(33):3327-32. PubMed ID: 23735678
[TBL] [Abstract][Full Text] [Related]
13. Effects of an epidermal growth factor receptor-based cancer vaccine on wound healing and inflammation processes in murine experimental models.
Fuentes D; Chacón L; Casacó A; Ledón N; Fernández N; Iglesias A; Hernández DR; Sánchez B; Pérez R
Int Wound J; 2014 Feb; 11(1):98-103. PubMed ID: 22947303
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy.
Gonzalez G; Crombet T; Torres F; Catala M; Alfonso L; Osorio M; Neninger E; Garcia B; Mulet A; Perez R; Lage R
Ann Oncol; 2003 Mar; 14(3):461-6. PubMed ID: 12598354
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine.
Carr A; Rodríguez E; Arango Mdel C; Camacho R; Osorio M; Gabri M; Carrillo G; Valdés Z; Bebelagua Y; Pérez R; Fernández LE
J Clin Oncol; 2003 Mar; 21(6):1015-21. PubMed ID: 12637465
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants.
Sánchez Ramírez J; Morera Díaz Y; Bequet-Romero M; Hernández-Bernal F; Selman-Housein Bernal KH; de la Torre Santos A; Santiesteban Álvarez ER; Martín Bauta Y; Bermúdez Badell CH; de la Torre Pupo J; Gavilondo JV; ; Ayala Avila M
BMC Immunol; 2017 Jul; 18(1):39. PubMed ID: 28747172
[TBL] [Abstract][Full Text] [Related]
17. Immunization with antigenic extracts of Leishmania associated with Montanide ISA 763 adjuvant induces partial protection in BALB/c mice against Leishmania (Leishmania) amazonensis infection.
Cargnelutti DE; Salomón MC; Celedon V; García Bustos MF; Morea G; Cuello-Carrión FD; Scodeller EA
J Microbiol Immunol Infect; 2016 Feb; 49(1):24-32. PubMed ID: 24662018
[TBL] [Abstract][Full Text] [Related]
18. Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: a report on safety and immunogenicity.
Guthmann MD; Bitton RJ; Carnero AJ; Gabri MR; Cinat G; Koliren L; Lewi D; Fernandez LE; Alonso DF; Gómez DE; Fainboim L
J Immunother; 2004; 27(6):442-51. PubMed ID: 15534488
[TBL] [Abstract][Full Text] [Related]
19. Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide.
Tobias J; Jasinska J; Baier K; Kundi M; Ede N; Zielinski C; Wiedermann U
BMC Cancer; 2017 Feb; 17(1):118. PubMed ID: 28183282
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the impact of manufacturing changes on the physicochemical properties and biological activity of Her1-ECD vaccine during product development.
Garcia Duardo K; Prieto Curbelo Y; Raymond Pous J; Rabasa Legón EY; Ramírez BS; Hernández KR; Castillo Vitoch A
Vaccine; 2015 Aug; 33(35):4292-9. PubMed ID: 26003492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]